Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings saw their own record-breaker this week. Parabilis Medicines secured $670 million when it hit the Nasdaq on Wednesday to drive forward the company's tumor-focused pipeline. The offering stole the crown from obesity biotech Kailera Therapeutics, whose $625 million IPO in April briefly set a ...